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Cell-based models have shown that response to che-
motherapy has a heritable component. We hypothesized
that in order to identify loci associated with treatment
outcome we should focus on cases known to have had
uniform chemotherapy for epithelial ovarian cancer. We
therefore performed a two-stage genome-wide associa-
tion study (GWAS) of progression free survival (PFS)
following first line carboplatin/paclitaxel chemotherapy
in ovarian cancer cases. In the first stage, we genotyped
(Illumina Omni1) 183 Australian cases selected using an
extreme phenotype design, and also included data on
134 cases from the TCGA and 68 from Mayo Clinic. In
this stage, 260 cases had ‘uniform’ treatment (“primary”
group: at least 4 cycles of carboplatin 5-6 AUC and
paclitaxel 135-175 mg/m
2 every three weeks) and 125
cases (“secondary”) had an unknown amount of carbo-
platin/paclitaxel chemotherapy. In the 2nd stage we gen-
otyped 156 of the top ranking genotyped and imputed
SNPs in 4660 cases (1080 ‘primary’ and 1433 ‘second-
ary’) from 11 sites in OCAC. The additive allelic asso-
ciation with the PFS was assessed in a Cox Proportional
Hazards model, adjusting for study site, histological sub-
type, grade, stage and residual disease. For the SNPs
with low minor allele frequencies, we ran permutations
to correct the asymptotic p-values. One SNP clearly
replicated in the 2nd stage. The associations in both
stages were strongest in the “primary” group (1
st stage
results for this imputed SNP: hazard Ratio (HR) per
minor allele=6.30, 95% CI=[4.26, 9.30], two-sided
asymptotic p-value=1.88e-6, permuted p-value=4.46e-5;
2
nd stage: HR per minor allele=3.37, 95% CI=[2.48,
4.62], one-sided asymptotic p-value=5e-5, permuted p-
value=2.9e-4; meta-analysis p-value corrected by permu-
tation=1.7e-7).
Furthermore, an independent cell-based GWAS con-
ducted using HapMap lymphoblastoid cell lines showed
that a more common SNP (MAF~4.5%) in moderate LD
with our reported SNP (r
2~0.28), was associated with
carboplatin sensitivity (p-value=9e-3). Both these SNPs
are located in a gene on chromosome 9 that is known
to be associated with circulating levels of high-density
lipoprotein cholesterol. Low levels of expression of this
gene are associated with poor outcome for both pro-
gression free (P=.017) and overall survival (P=.001) from
serous ovarian cancer in The Cancer Genome Atlas.
We are now genotyping a panel of rare and common
SNPs in this gene in additional validation cohorts from
OCAC and conducting additional experiments to evalu-
ate its biological relevance with respect to treatment
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metabolism as a determinant of response to chemother-
apy. Our findings may provide some insight into the
suggested role of statins in improving outcome for ovar-
ian cancer.
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